Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 6/20 | 0.75 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.75 |
| ▸ | HTR3B | O95264 | 4/20 | 0.75 |
| ▸ | HTR3A | P46098 | 4/20 | 0.75 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.75 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.75 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.75 |
| ▸ | HTR1A | P08908 | 3/20 | 0.53 |
| ▸ | HTR7 | P34969 | 3/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | HTR6 | P50406 | 4/20 | 0.50 |
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 2/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | NCF1 | P14598 | 1/20 | 0.47 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL28163332 | 0.98 | ADRB1 (0.72) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Hydrochloric Acid SCHEMBL11019815 | 0.98 | ADRB1 (0.72) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Ammonia Solution, Strong SCHEMBL20512352 | 0.98 | ADRB1 (0.72) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL17423648 | 0.90 | ADRB1 (0.68) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Thiourea SCHEMBL11018060 | 0.89 | ADRB1 (0.60) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Isothiocyanate SCHEMBL11037708 | 0.89 | ADRB1 (0.60) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Isothiocyanate SCHEMBL11021338 | 0.87 | ADRB1 (0.58) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL2051022 | 0.87 | HTR3A (0.57) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Phenylpiperazine SCHEMBL29135595 | 0.86 | ADRB1 (1.00) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| Phenylpiperazine SCHEMBL55125 | 0.86 | ADRB1 (1.00) | ADRB1HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116157490-A | Spiro metallized iridium emitters for OLED applications | 香港大学 | 2023-05-23 | — | — | CN | claimed |
| CN-111171049-A | Tyrosine kinase inhibitors and uses thereof | 山东轩竹医药科技有限公司 | 2020-05-19 | — | — | CN | claimed |
| CN-111100073-A | Benzimidazole derivative containing halogen and preparation method and application thereof | 桂林理工大学 | 2020-05-05 | — | — | CN | claimed |
| US-10370403-B2 | Methods for the synthesis of ceragenins | BRIGHAM YOUNG UNIVERSITY (US) | 2019-08-06 | — | — | US | claimed |
| CN-105944581-B | A kind of anion responsiveness Pickering lotion and its preparation method and application | 辽宁大学 | 2019-01-01 | — | — | CN | claimed |
| US-20170283860-A1 | METHODS AND COMPOSITIONS FOR THE REMOVAL OF ALDEHYDE ADDUCTS AND CROSSLINKS FROM BIOMOLECULES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2017-10-05 | — | — | US | claimed |
| WO-2016044313-A1 | METHODS AND COMPOSITIONS FOR THE REMOVAL OF ALDEHYDE ADDUCTS AND CROSSLINKS FROM BIOMOLECULES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-03-24 | — | — | WO | claimed |
| EP-2094667-B1 | SALTS CONSISTING OF PENTAFLUORPHENYLIMIDE ANIONS AND THEIR USE AS IONIC LIQUIDS | PHILIPPS UNIVERSITÄT MARBURG (DE) | 2016-01-13 | — | — | EP | claimed |
| US-8669114-B2 | Hydrophobic ionic liquids | PHILIPPS-UNIVERSITAET MARBURG (DE) | 2014-03-11 | — | — | US | claimed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | claimed |
| US-20020002749-A1 | Indolizine derivatives, compositions comprising at least one coupler chosen from indolizine derivatives and at least one oxidation base, and methods for using same | BRETON PHILIPPE (FR) | 2002-01-10 | — | — | US | claimed |
| US-20010044974-A1 | Compositions for dyeing keratin fibers, containing cationic indolizine derivatives, and dyeing process | BRETON PHILIPPE (FR) | 2001-11-29 | — | — | US | claimed |
| US-6008230-A | TREATING BONE DISEASES CAUSED BY ABNORMAL BONE METABOLISM IN HUMAN BEING OR ANIMALS AS THE INHIBITORS OF BONE RESORPTION OR THE INHIBITORS OF BONE METASTASIS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-12-28 | — | — | US | claimed |
| EP-0876345-A1 | HETEROCYCLIC COMPOUNDS AS H+-ATPASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-11-11 | — | — | EP | claimed |
| EP-0580008-B1 | Phenylimidazolidine Derivatives, their preparation and use | HOECHST AG (DE) | 1998-07-08 | — | — | EP | claimed |
| WO-1997014681-A1 | HETEROCYCLIC COMPOUNDS AS H+-ATPASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-04-24 | — | — | WO | claimed |
| US-5424293-A | Anticoagulants of platelet aggregation; osteoclast antagonist for treating osteoporosis | CASSELLA AG (DE) | 1995-06-13 | — | — | US | claimed |
| EP-0349243-B1 | ANTIVIRAL COMBINATIONS AND COMPOUNDS THEREFOR | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-04-01 | — | — | EP | claimed |
| EP-0349243-A2 | Antiviral combinations and compounds therefor | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-01-03 | — | — | EP | claimed |
| US-4769177-A | Electrically conductive and antistatic moulding compositions | BAYER AKTIENGESELLSCHAFT (DE) | 1988-09-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002749-A1 | Indolizine derivatives, compositions comprising at least one coupler chosen from indolizine derivatives and at least one oxidation base, and methods for using same | KRT18, INMT, IDO1 | ADRB1 2072/4885HTR3E 1235/4885HTR3B 1400/4885 |
| US-20010044974-A1 | Compositions for dyeing keratin fibers, containing cationic indolizine derivatives, and dyeing process | KRT18, INMT, KMO | ADRB1 2157/4885HTR3E 990/4885HTR3B 1381/4885 |
| US-10370403-B2 | Methods for the synthesis of ceragenins | CALCA, CAPG, MYADM | ADRB1 4680/4885HTR3E 4718/4885HTR3B 4719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.